Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma

Key Points

• Community hematologists and oncologists report varied approaches to minimal residual disease testing in multiple myeloma.
• Testing influences clinical decision-making, with emphasis on adapting treatment based on MRD results.
• Barriers include access to MRD testing and understanding of clinical implications among patients and providers.
• Patterns of MRD testing usage vary significantly across different healthcare practice settings.

Abstract